Solid Biosciences (NasdaqGS:SLDB) - Share price, News & Analysis

SLDB fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

SLDB Stock Overview

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States.

Rewards

Revenue is forecast to grow 55.02% per year

Risk Analysis

Earnings are forecast to decline by an average of 9.8% per year for the next 3 years

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

+ 1 more risk

Solid Biosciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Solid Biosciences
Historical stock prices
Current Share Price	US$0.55
52 Week High	US$4.92
52 Week Low	US$0.42
Beta	1.54
1 Month Change	-32.79%
3 Month Change	-41.30%
1 Year Change	-86.42%
3 Year Change	-90.11%
5 Year Change	n/a
Change since IPO	-97.59%

Recent News & Updates

Apr 30

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

It's shaping up to be a tough period for Solid Biosciences Inc. ( NASDAQ:SLDB ), which a week ago released some...

Apr 28

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

The latest analyst coverage could presage a bad day for Solid Biosciences Inc. ( NASDAQ:SLDB ), with the analysts...

Shareholder Returns

	SLDB	US Biotechs	US Market
7D	8.2%	1.4%	-2.7%
1Y	-86.4%	-21.7%	-12.9%

Return vs Industry: SLDB underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: SLDB underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is SLDB's price volatile compared to industry and market?
SLDB volatility
SLDB Average Weekly Movement	18.2%
Biotechs Industry Average Movement	12.4%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	2.9%

Stable Share Price: SLDB is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: SLDB's weekly volatility has increased from 12% to 18% over the past year.

About the Company

Founded	Employees	CEO	Website
2013	104	Ilan Ganot	https://www.solidbio.com

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company’s lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients’ muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids.

Solid Biosciences Fundamentals Summary

How do Solid Biosciences's earnings and revenue compare to its market cap?
SLDB fundamental statistics
Market Cap	US$61.58m
Earnings (TTM)	-US$80.62m
Revenue (TTM)	US$12.21m

5.0x

P/S Ratio

-0.8x

P/E Ratio

Is SLDB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
SLDB income statement (TTM)
Revenue	US$12.21m
Cost of Revenue	US$5.74m
Gross Profit	US$6.47m
Other Expenses	US$87.09m
Earnings	-US$80.62m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.71
Gross Margin	53.00%
Net Profit Margin	-660.25%
Debt/Equity Ratio	0%

How did SLDB perform over the long term?

See historical performance and comparison

Valuation

Is Solid Biosciences undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

0.33x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SLDB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SLDB's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: SLDB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: SLDB is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SLDB's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: SLDB is good value based on its PB Ratio (0.3x) compared to the US Biotechs industry average (1.5x).

Future Growth

How is Solid Biosciences forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-9.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLDB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SLDB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SLDB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SLDB's revenue (55% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: SLDB's revenue (55% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SLDB is forecast to be unprofitable in 3 years.

Past Performance

How has Solid Biosciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-9.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SLDB is currently unprofitable.

Growing Profit Margin: SLDB is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: SLDB is unprofitable, and losses have increased over the past 5 years at a rate of 9.8% per year.

Accelerating Growth: Unable to compare SLDB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SLDB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: SLDB has a negative Return on Equity (-43.46%), as it is currently unprofitable.

Financial Health

How is Solid Biosciences's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SLDB's short term assets ($198.6M) exceed its short term liabilities ($21.7M).

Long Term Liabilities: SLDB's short term assets ($198.6M) exceed its long term liabilities ($301.0K).

Debt to Equity History and Analysis

Debt Level: SLDB is debt free.

Reducing Debt: SLDB has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SLDB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SLDB has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 8.3% each year.

Dividend

What is Solid Biosciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SLDB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SLDB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SLDB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SLDB's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SLDB has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure

CEO

Ilan Ganot (47 yo)

9.33yrs

Tenure

US$3,293,809

Compensation

Mr. Ilan Ganot is Co- Founder of Solid Biosciences Inc. and has been its Chief Executive Officer and Director since 2013. He serves as the President of Solid Biosciences Inc. since June 26, 2018. He is al...

CEO Compensation Analysis

Compensation vs Market: Ilan's total compensation ($USD3.29M) is above average for companies of similar size in the US market ($USD770.27K).

Compensation vs Earnings: Ilan's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: SLDB's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Experienced Board: SLDB's board of directors are considered experienced (5.8 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/22 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31